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Abstract 
Introduction: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunol-
ogy (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life obser-
vational research to identify high-quality real-life asthma studies that could be considered within future guideline 
development.
Methods: The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis 
of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, ver-
sion underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading 
to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies 
identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies 
may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected 
through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and 
particle size on asthma treatment effectiveness.
Results: Although highlighting a general lack of high-quality real-life effectiveness observational research on these 
clinically important topics, the analysis provided insights into how identified observational studies might inform 
asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers.
Conclusions: Using such quality appraisal tools is mandatory to assess whether specific observational real-life effec-
tiveness studies can be used to inform guideline development and/or decision-making in clinical practice.
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Introduction: background and objectives
Randomised controlled trials (RCTs) are required to 
establish the efficacy and explore the safety of asthma 
treatments, but are insufficient to provide holistic evi-
dence on the benefit/risk ratio of interventions when 
offered, initiated or used in the heterogeneous asthma 
patient populations and care settings that exist outside 
the trial environment. Registration asthma and allergy 
RCTs are designed to maximize chances of observ-
ing efficacy [1]. To do so, they impose a standardised 
level of care (often more intensive and extensive than 
is feasible in routine care) and systematically exclude 
patients presenting with characteristics that could 
modulate treatment responses such as smoking, obe-
sity, poor adherence, inhaler misuse, poor reversibility, 
possible overlap with chronic obstructive pulmonary 
disease (COPD) or other comorbidities [2–7]. In this 
way, registration RCTs guarantee high internal validity 
to obtain market authorization of the drug but do not 
provide sufficient evidence to guide decision-making 
in routine clinical practice, since they exclude a sig-
nificant proportion of the real-life asthmatic popula-
tion [8]. Excluded patients may also represent subsets 
of the population in whom achieving asthma control is 
more difficult, i.e. those who warrant increased atten-
tion and monitoring. Therefore, it is necessary to test 
the external validity of the findings of the registration 
RCTs: their generalizability and their applicability to 
the general asthma population and to specific sub-
groups usually excluded from RCTs [9]. It is important 
to find reliable research methods to complement RCTs 
and broaden the evidence-base available to inform 
clinical practice decision-making [10–12]. Several 
study designs are available to reach this goal, including 
pragmatic randomized trials and observational studies, 
which can be prospective or historical, the latter relying 
on clinical cohorts, registries or databases [1, 13]. Phase 
IV comparative effectiveness studies are crucial not 
only to clinicians, but also to other stakeholders such as 
guideline developers and healthcare policy makers [14]. 
They can also generate new hypotheses to be tested in 
RCTs or other adapted study designs.
In observational research as well as in RCTs, ensuring 
high-quality methodology is crucial to avoid biases that 
would compromise the reliability and validity of results 
[15]. Following the GRADE methodology for evidence 
appraisal, RCTs are initially considered as providing high 
levels of evidence while observational studies are set at a 
lower level [16, 17]. Accounting for the quality of avail-
able studies, which determines the risk of biases, levels of 
evidence can be downgraded for RCTs and upgraded for 
observational research (Fig. 1) [18]. However, while qual-
ity standards for RCTs are well-defined and extensively 
disseminated, e.g., by the CONSORT statements [19, 20], 
this is less so in the field of observational comparative 
effectiveness research.
A number of frameworks have been proposed to help 
characterise the extent to which a study design reflects 
pragmatic aspects or real-life patients and practice [1, 
21]. One of these frameworks (developed by respiratory 
clinicians but more generally applicable) relies on two 
axes, namely the population’s characteristics and the so-
called “ecology of care”, which encompasses the context 
in which care is delivered (e.g., routine primary care vs. 
controlled conditions with regular visits to specifically 
trained healthcare professionals, as in most registration 
RCTs) (Fig. 2) [1]. This framework was proposed by the 
Respiratory Effectiveness Group (REG), an academic 
non-profit organization created in 2012 with the aim of 
promoting high-quality real-life research in respiratory 
diseases. Several tools to guide the design and report-
ing of observational research have also been developed, 
sometimes using systematic and rigorous processes [22–
27]. While these provide invaluable insights and recom-
mendations for evidence generation, they have not been 
specifically designed for the evaluation of published 
(comparative) effectiveness research.
To address this, REG and the European Academy of 
Allergy & Clinical Immunology (EAACI) convened a 
joint Task Force to set and test quality standards for 
Fig. 1 GRADE assessment of the strength of evidence of individual studies and systematic reviews. Adapted from [18]
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observational comparative effectiveness research (CER) 
in asthma, and to assess the extent to which the evidence 
from such studies might complement the results of RCTs. 
The aim of the current manuscript is to provide an over-
view of how this Task Force developed a quality assess-
ment tool and applied it to selected PICOT questions for 
which RCTs provided only limited evidence. The pur-
pose of this paper is not to provide an extensive descrip-
tion of the tool development process, nor the detailed 
results of the literature review; these will be the topics of 
additional publications (see [28] for details on the tool’s 
development).
Methods
The initial work comprised two simultaneous processes: 
[1] the development of a quality assessment tool through 
a synthesis of Task Force expertise and recommenda-
tions within existing relevant publications and [2] the 
selection of relevant research topics and identification 
of corresponding articles that would be used to test the 
tool. Once the tool was finalised (following pilot test-
ing and iterative refinement), it was used to appraise 
the retrieved literature. Studies achieving sufficiently 
high quality scores were then assessed to determine the 
extent to which they offered novel data and insights that 
could influence clinical practice and inform guidelines. A 
Task Force activity schedule summary is presented in the 
Additional file 1: Table S1.
Development and testing of the quality assessment tool
Full details of the REal Life EVidence AssessmeNt Tool 
(RELEVANT) development and assessment process are 
detailed in a dedicated article [28]. In summary, a sys-
tematic review of related quality tools and recommenda-
tions for effectiveness research proposed in the published 
literature was performed [22–27]. Appropriate quality 
assessment domains and specific sub-items were identi-
fied, agreed through Task Force discussions and used to 
build a first version of RELEVANT. The domains were: 
background, study design, measures, analysis, presenta-
tion of results, discussion and interpretation, conclusions 
and reporting of possible conflicts of interest including, 
but not restricted to, study funding. For each domain, 
items (n = 25 altogether) were divided into primary and 
secondary/supporting. The resulting assessment grid was 
then tested by 9 members of the Task Force divided in 
two groups, each assessing three articles selected by the 
Task Force leads. For each item, the agreement between 
raters was calculated before being summarized for all pri-
mary items, all secondary items and all (primary and sec-
ondary) items combined. Three of the papers reviewed 
Fig. 2 REG research framework. Reproduced with permission from [1]
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considered the relationship between adherence and out-
comes in patients with asthma, and three papers exam-
ined the relationship between particle size or device type 
and asthma outcomes [29–34]. Rater comments on the 
ease of implementation of the RELEVANT tool were col-
lected as free text using a dedicated table. Levels of agree-
ment and rater comments were discussed face-to-face at 
a Task Force meeting and the tool was refined and for-
matted to be usable on a web-based platform. The result-
ing version of the tool was tested on a larger basis by 22 
raters distributed into 3 groups reviewing 2 papers each. 
There were two papers on the relation between adher-
ence and asthma outcomes, two on the relation between 
drug persistence and healthcare resource utilization and 
two on the relation between particle size and outcomes 
[35–40]. Additional free-text feedback was captured and 
used to guide further refinements and to finalise the first 
version of RELEVANT.
Selection of topics and literature search
A first set of 21 PICOT [(P)opulation selected for the 
study, (I)ntervention, (C)omparator, (O)utcome measures 
and (T)ime—duration] [41] questions was identified dur-
ing a Task Force meeting. The questions were selected 
based on their relevance for asthma management, limited 
ability of available RCTs to provide robust answers and 
potential of observational research to address them. Dis-
cussions in a plenary session led to the prioritization of 9 
PICOT questions. An online poll was conducted among 
REG members and EAACI representatives to prioritise 
the topics and 4 PICOT questions were finally selected 
to ensure feasibility of delivery. The literature search was 
conducted using the Medline and EMBASE bibliometric 
databases to identify asthma effectiveness studies. Search 
results were then categorised to relevance to the selected 
PICOT questions (see the Additional file 1 for details on 
the search strategy, Table S2). The flow diagram shown in 
Fig. 3 depicts the main steps of the selection process.
Assessment of the literature
Papers considered of sufficient quality were sent to at 
least two raters each with a reading grid (see Additional 
file  1: Table  S3) comprising the following items: sum-
mary of methods (studied population, intervention, 
outcomes, setting), summary of results (magnitude of 
differences/robustness) and possible remaining biases. 
The list of raters is available in the Additional file  1: 
Table S4. Each paper was sent to a third rater when there 
Fig. 3 Flow diagram for inclusion/exclusion of articles
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was discordance in the conclusions from the two initial 
raters. For each PICOT question, a summary table was 
built, mentioning, for each article, the type of source (e.g. 
claims database or prospective cohort), the main conclu-
sion, the corresponding level of evidence proposed based 
on GRADE assessment, the possible impact on clinical 
practice and whether similar evidence was available from 
RCTs. Summary tables were presented and discussed 
during a dedicated plenary session at the REG Summit in 
June 2016.
Results
RELEVANT: the REal Life EVidence AssessmeNt Tool
RELEVANT is presented in Table  1. For each quality 
domain, sub-items are categorised as primary or second-
ary items. The general principle for use of the tool is that 
a study should only be eligible to inform guideline devel-
opment (or a similar processes) if all primary items are 
satisfied. Thereafter, secondary items can be used to fur-
ther appraise non-essential, but pertinent aspects of pub-
lished studies. Thus, the tool exists in two formats: [1] a 
version specific to guideline development, in which sec-
ondary items appear to the rater only when all primary 
quality items are satisfied, and [2] a version for more gen-
eral quality appraisal in which all primary and secondary 
items are immediately visible.
The final list of 21 items within RELEVANT was 
informed by appraisal of inter-rater agreement. Initial 
agreement was poor (≤ 50%) for 8/25 items when first 
piloted among Task Force members. Iterative refinement 
was then based on rater feedback and removal of ambi-
guity in time language to avoid potential for uncertainty 
or differing interpretation. This resulted in a marked 
improvement in concordance between raters, to ≥ 73% 
for all primary and ≥ 69% for all secondary items when 
averaged over the three rating groups. Further details on 
concordance are available in the accompanying method-
ology paper [28].
PICOT questions
The four selected PICOT questions (numbered follow-
ing their rank during the selection process) dealt with the 
influence of adherence/persistence on asthma outcomes, 
the influence of smoking on asthma outcomes and treat-
ment effectiveness, the impact of the inhaler device on 
Table 1 RELEVANT REG quality assessment tool for observational research
Primary items
 1. Background 1.1. Clearly stated research question
 2. Design 2.1 Population defined
2.2. Comparison groups defined and justified
 3. Measures 3.1. (If relevant), exposure (e.g. treatment) is clearly defined
3.2. Primary outcomes defined
 4. Analysis 4.1. Potential confounders are addressed
4.2. Study groups are compared at baseline
 5. Results 5.1. Results are clearly presented for all primary and secondary endpoints as well as confounders
 6. Discussion/interpretation 6.1. Results consistent with known information or if not, an explanation is provided
6.2 The clinical relevance of the results is discussed
 7. Conflict of interests 7.1. Potential conflicts of interest, including study funding, are stated
Secondary items
 1. Background 1.1. The research is based on a review of the background literature (ideal standard is a systematic review)
 2. Design 2.1. Evidence of a priori design, e.g. protocol registration in a dedicated website
2.2 Population justified
2.3 The data source (or database), as described, contains adequate exposures (if relevant) and outcome variables to 
answer the research question
2.4 Setting justified
 3. Measures 3.1 Sample size/Power pre-specified
 4. Analysis NO SECONDARY ITEMS
 5. Results 5.1. Flow chart explaining all exclusions and individuals screened or selected at each stage of defining the final sample
5.2. The authors describe the statistical uncertainty of their findings (e.g. p-values, confidence intervals)
5.3. The extent of missing data is reported
 6. Discussion/interpretation 6.1. Possible biases and/or confounding factors described
 7. Conflict of interests NO SECONDARY ITEMS
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asthma outcomes and the relation between particle size 
of maintenance therapy and asthma outcomes (Table 2).
Selected articles
Altogether, 46 relevant articles were identified: n = 24 for 
PICOT question 1 [7, 29, 35, 36, 38, 42–59], 7 for PICOT 
question 2 [34, 39, 60–64], 3 for PICOT question 3 [33, 
65, 66] and 12 for PICOT question 4 [32, 40, 67–76]. Fig-
ure  4 shows the results of the quality assessment of all 
papers by PICOT question and Fig.  5 provides a sum-
mary of failed items (Fig. 5a) and domains (Fig. 5b). The 
detailed quality assessment of all selected articles is pre-
sented in the Additional file 1: Table S5.
Literature analysis
A summary of the literature analysis is presented in 
Tables  3, 4 and 5. Study results are presented in a con-
cise way due to space limitations and since more details 
would actually be out of the scope of the present man-
uscript. Nonetheless, the main limitation of currently 
available clinical or claims database studies was found 
to be the paucity or lack of detailed clinical data regard-
ing: [1] asthma control as assessed by validated ques-
tionnaires, [2] severity as assessed by symptoms and 
lung function, [3] comorbidities, as evidenced by either 
symptoms suggestive of comorbidities such as rhinitis 
or gastro-oesophageal reflux disease, or physician diag-
noses of comorbidities. As a consequence, authors used 
available proxy measures, including: [1] short-acting 
beta-agonist (SABA) use and exacerbations as mark-
ers of control; [2] inhaled corticosteroid (ICS) dose and 
add-on treatments for severity, and [3] prescribed thera-
pies in place of comorbidity diagnoses. In most retained 
studies, these factors were used to match and/or adjust 
analyses, a required feature to increase the robustness 
of results. Use of such statistical approaches allowed the 
level of evidence to be raised to moderate but not high 
as residual confounding by hidden factors could not be 
ruled out; for instance, detailed data on lifestyle behav-
iours (such as smoking, diet and physical activity) are 
Table 2 Selected PICOT questions
Question Influence of adherence to ICS 
therapy on asthma outcomes
Influence of device type 
for ICS therapy on asthma 
outcomes
Influence of smoking 
on asthma outcomes 
in patients receiving ICS 
therapy
Influence of ICS particle size 
on asthma outcomes
Population Asthmatics of all ages prescribed 
regular maintenance ICS
Asthmatics of all ages pre-
scribed regular maintenance 
ICS
Asthmatics of all ages pre-
scribed regular maintenance 
ICS
Asthmatics of all ages prescribed 
regular maintenance ICS
Intervention Adherence to recommended 
therapy
Different inhaler devices/deliv-
ery systems
Smokers Extra-fine particles ICS
Comparison Different levels of adherence 
(e.g. 0–25%, 25–50%, 50–75%, 
over 75%)
Different inhaler systems (pMDI, 
breath-activated MDI, DPI) for 
delivering the same molecule
Ex/non-smokers Fine particles ICS
Outcomes Exacerbations, admissions, 
symptoms, QOL
Exacerbations, admissions, 
symptoms, QOL
Exacerbations, admissions, 
symptoms, QOL
Exacerbations, admissions, symp-
toms, QOL
Time frame ≥ 12 months ≥ 12 months ≥ 12 months ≥ 12 months
Fig. 4 distribution of papers by quality rating within selected PICOT questions. TBC refers to a minority of papers that got only one rating, so that 
final rating remained to be consolidated
Page 7 of 17Roche et al. Clin Transl Allergy            (2019) 9:20 
frequently lacking and body mass index is absent in sev-
eral databases. The results of observational studies con-
sidered of sufficient quality (all 11 primary items fulfilled) 
suggest several conclusions regarding the corresponding 
PICOT questions.
Influence of adherence to ICS therapy on asthma outcomes 
(Table 3) [38, 42–49]
All papers retained for analysis following RELEVANT-
based quality assessments reported an association 
between lower adherence to maintenance therapy and 
poorer control, as assessed by SABA use or markers of 
exacerbations (e.g. oral corticosteroid treatment or hos-
pital contacts: emergency room visits, hospitalizations). 
More specific findings relating to drug classes were 
reported: oral leukotriene receptor antagonist (LTRA) 
therapy appeared to be more effective than ICS in obtain-
ing control in non-adherent patients; the opposite was 
true for adherent patients [38]. Some aspects included 
in the PICO question could not be addressed: although 
several papers used the medication possession ratio 
(MPR; the ratio of the period covered by drug dispensa-
tions by the total observation period) to assess level of 
adherence [36, 47, 50, 51, 77], they did not determine a 
minimal threshold of adherence below which asthma 
outcomes worsen. In addition they were not designed to 
assess whether a “dose–response” relationship could be 
described.
Influence of device type for ICS therapy on asthma outcomes 
(Table 4) [34, 39, 60–63]
Papers dealing with device choice suggested that limiting 
the number of different inhaler device types prescribed to 
an individual patient was associated with better asthma 
outcomes, while switching devices outside the context of 
a dedicated medical visit was associated with a greater 
Fig. 5 proportion of failed items by domains (a) and items b of the quality assessment tool (see Table 1 for details on the items’ labelling)
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Table 3 Summary table of  literature analysis, PICOT question 1: influence of  adherence to  ICS therapy on  asthma 
outcomes
SABA short-acting beta2 agonist, LABA long-acting beta2 agonist, ICS inhaled corticosteroid, LTRA leukotriene-receptor antagonist, MF mometasone furoate, FP 
fluticasone propionate, D database, PC prospective cohort, S survey, M matched, A adjusted, RCT randomized controlled trial, MPR medication possession ratio, ED 
emergency department, ACQ asthma control questionnaire, TF task force
a Opposite finding regarding the risk of severe asthma exacerbation in several trials
Reference Statement Type 
of data 
source
Final level 
of evidence (see 
Fig. 1)
Possible impact 
on clinical practice (TF 
opinion)
Similar evidence 
available from RCTs
Williams et al. [45] Low adherence increases the risk of ED 
visits and oral steroid treatment
D-M Moderate Yes No
Taegtmeyer et al. [46] Lower ACQ improvement associated 
with low adherence
PC-A Moderate Yes No
Laforest et al. [47] Low adherence (MPR) associated with 
poorer control and more hospital 
contacts and oral steroid courses
PC-A Moderate Yes No
Laforest et al. [48] Low adherence (MPR) increases the 
risk of oral steroid treatment and 
hospitalization
D-A Moderate Yes No
Sadatsafavi et al. [31] Risk of asthma-related hospitalization 
lower with ICS-containing regimen 
than LABA alone
D-M Moderate Yes No
Risk of asthma-related hospitalization 
similar between ICS and ICS-LABA
D-M Moderate Yes Noa
Risk of asthma-related hospitalization 
increases when ICS treatment is 
irregular
D-M Moderate Yes No
Friedman et al. [43] Adherence and SABA use are better 
with MF than FP DPIs, with no differ-
ence in other clinical outcomes
D-M Moderate No No
Campbell et al. [44] Shifting drug costs to patients 
decreases adherence and impairs 
asthma outcomes
D Moderate Yes No
Tan et al. [38] In adherent patients, ICS > LTRA D + S Moderate (D), low (S) Yes In part (pragmatic RCT)
In non-adherent patients, ICS < LTRA D + S Moderate (D), low (S) Yes In part (pragmatic RCT)
Table 4 Summary table of  literature analysis, PICOT question 2: influence of  device type for  ICS therapy on  asthma 
outcomes
DPI dry powder inhaler, BAI breath-actuated inhaler, pMDI pressurized metered-dose inhaler, FP fluticasone propionate, SAL salmeterol, D database, M matched, A 
adjusted, TF task force
Reference Statement Type 
of data 
source
Final level 
of evidence (see 
Fig. 1)
Possible impact 
on clinical practice (TF 
opinion)
Similar evidence 
available 
from RCTs
Price et al. [60] One single device for maintenance treatment is 
better than mixed devices in terms of control 
and severe exacerbations
D-A Moderate Yes No
Thomas et al. [62] Switching devices (DPI to pMDI or BAI or other 
DPI -BAI to pMDI or other BAI) is associated with 
poorer outcomes
D-M-A Moderate Yes No
Price et al. [61] pMDI > DPI to administer FP/SAL, in terms of 
asthma outcomes
D-M-A Moderate Uncertain (cause?) No
Price et al. [34] BAI and DPI better than pMDI for several asthma 
outcomes
D-A Moderate Uncertain (cause?) No
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risk of a loss of control [60, 62]. One study found superi-
ority of a metered dose inhaler (MDI) over a dry powder 
inhaler (DPI) for the administration of ICS/LABA fixed-
dose combination [61]. However, another study by the 
same group found breath-actuated metered dose inhalers 
and DPIs to be superior to MDIs for the administration 
of ICS for several asthma outcomes [34].
Influence of smoking on asthma outcomes in patients 
receiving ICS therapy (Table 5) [33, 65]
A prospective cohort study did not find differential treat-
ment effects of an ICS-LABA fixed dose combination for 
patients with different smoking behaviours, but asthma 
patients with a current smoking status had poorer out-
comes overall [33]. Another study suggested that extra-
fine ICS could be more suitable to control airways 
inflammation in smokers and ex-smokers than larger 
particle ICS alternatives [65].
Influence of ICS particle size on asthma outcomes (Tables 6, 
7) [32, 40, 67–72]
Several analyses, mostly by the same group [32, 40, 
67–71], were performed in various populations (chil-
dren, adults) using various databases (UK, US) and 
found superiority of extra-fine versus larger particle ICS 
administered alone or as part of an ICS-LABA fixed dose 
combination in asthma [32, 40, 67–72]. Accordingly, eco-
nomic analyses using these results suggested extra-fine 
ICS was a dominant strategy as compared with larger 
particle ICS alternatives [32, 69].
Discussion
The REG-EAACI Task Force on quality standards in 
asthma comparative effectiveness research defined tar-
get quality standards and developed a quality assessment 
tool—RELEVANT—to appraise published observa-
tional effectiveness studies. The definition of standards 
and development of the tool aimed to provide a simple 
assessment grid for paper-based or web-based use, spe-
cifically designed for the evaluation of published effec-
tiveness research. They were based on previous initiatives 
in this area [22–27] and iterative testing and refinement. 
RELEVANT follows a two-step process: first assessing 
primary, critical items; then appraising secondary, ben-
eficial quality items. When used in the context of deci-
sion-making or guidelines development, it is strongly 
suggested to stop the assessment and discard the study 
if any one primary criterion is not satisfied. One major 
challenge in that respect is to distinguish between a 
methodological flaw and insufficient reporting. The latter 
Table 5 Summary table of  literature analysis, PICOT question 3: influence of  smoking on  asthma outcomes in  patients 
receiving ICS therapy
Reference Statement Type 
of data 
source
Final level 
of evidence (see 
Fig. 1)
Possible impact 
on clinical practice (TF 
opinion)
Similar evidence 
available 
from RCTs
Brusselle et al. [33] Lower asthma control in smokers but same treat-
ment benefit irrespective of smoking status
PC Low (see text) No No
Roche et al. [65] Better outcomes with extra-fine versus standard 
size particle ICS, larger differences in current 
and ex-smokers
D-M-A Moderate Uncertain (exploratory) No
Table 6 Summary table of literature analysis, PICOT question 4: influence of ICS particle size on asthma outcomes
Reference Statement Type of data 
source
Final level 
of evidence (see 
Fig. 1)
Possible impact on clinical 
practice (TF opinion)
Similar evidence 
available 
from RCTs
Van Aalderen et al. [67] See Table 7 D-M-A Moderate Yes No
Martin et al. [68] See Table 7 D-M-A Moderate Yes No
Colice et al. [69] See Table 7 D-M-A Moderate Yes No
Price et al. [70] See Table 7 D-M-A Moderate Yes No
Price et al. [71] See Table 7 D-M-A Moderate Yes No
Barnes et al. [40] See Table 7 D-M-A Moderate Yes No
Price et al. [32] See Table 7 D-M-A Moderate Yes No
Allegra et al. [72] PC-A Low (selection bias, 
secondary objec-
tive)
No No
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can be overcome (e.g. by contacting the authors for clari-
fications), but may also be improved through awareness 
of the RELEVANT tool.
Four PICOT questions were selected through a poll 
among the Task Force and members of REG and EAACI, 
and related observational studies identified through a 
systematic literature search among bibliometric research 
databases. Retrieved records were then quality appraised 
using the RELEVANT tool. Several of the papers were 
assessed as being of sufficiently good quality to allow an 
increase in their level of evidence from low to moderate 
following a GRADE-like process. For all PICOT ques-
tions of interest, assessed observational studies yielded 
results with possible impact on clinical practice in areas 
where similar evidence from RCTs is lacking. Altogether, 
this suggests that RELEVANT could become a useful tool 
to appraise the evidence from observational studies as 
part of a guideline development process as well as offer-
ing wider utility for more general literature reading and 
appraisal, and to inform research development.
Relevant
A quality assessment instrument needs to offer ease 
of use and sufficient robustness to ensure confidence 
in its grading. This requires the items to be clear, easily 
understood and rated similarly by different raters. While 
the detailed tool development process is the topic of a 
dedicated paper [28], it can be emphasized here that the 
final tool was considered easy to use by members of the 
REG and EAACI networks who were involved in the final 
phase. Reaching a 100% inter-rater agreement is prob-
ably not realistic considering the heterogeneity of meth-
odology reporting in published papers, but fair levels of 
agreement were obtained in the implementation phase 
(≥ 73% for primary items and ≥ 69% for secondary ones 
averaged over the three raters).
PICOT questions
An interesting observation permitted by this process was 
the high number of PICOT questions (n = 21) identi-
fied during the first round of selection by the Task Force 
and its REG and EAACI correspondents. This outlines 
the evidence gaps that are still present regarding asthma 
treatment, despite the considerable research interest for 
this common but still insufficiently controlled disease. 
This also contrasts with the high number of RCTs assess-
ing the efficacy of various components of asthma care, 
including both medications and non-pharmacological 
approaches such as education or integrated care. This dis-
crepancy illustrates that classical RCTs are not sufficient 
Table 7 PICOT question 4: influence of  ICS particle size on asthma outcomes: summary of results of matched database 
studies
EF extra-fine, St standard size, BDP beclomethasone dipropionate, SAL salmeterol; FOR, formoterol, FP fluticasone propionate, pMDI pressurized metered-dose inhaler
Reference Outcomes Treatments Population Database Results
Van Aalderen et al. [67] Clinical BDP pMDI
St versus EF
Initiation
Step-up
Vs LABA
Children 5–11 UK (CPRD)
US (Optuminsight)
EF > St
EF = adding LABA
Price et al. [70] Clinical BDP pMDI
St versus EF
Initiation
Switch
12–80 UK GPRD CPRD EF > St
Price et al. [71] Clinical pMDI
St FP versus EF BDP
Initiation
Step-up
5–60 UK GPRD EF ≥ St at lower doses
Barnes et al. [40] Clinical BDP pMDI
St versus EF
Initiation
Step-up
5–60 UK GPRD EF > St
Martin et al. [68] C-E BDP/FP pMDI
St versus EF
Initiation
12–60/12–80 UK/US EF dominant
Colice et al. [69] C-E pMDI
St FP versus EF BDP
Initiation
Step-up
12–80 UK/US EF ≥ St at lower doses and costs
Price et al. [32] C-E St FP-SAL versus EF BDP-FOR 18–80 UK GPRD CPRD EF ≥ St at lower doses
EF dominant
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to answer all questions regarding real-life effectiveness 
of therapeutic strategies, and need to be complemented 
by dedicated studies designed to reflect better the range 
of patients and care settings that exist in routine clinical 
practice [1, 9, 13, 14].
Literature search: rationale and quantitative results
The initial steps of the process confirmed that conducting 
a search specific to observational effectiveness research 
is challenging given the lack of standardised and spe-
cific terminology/nomenclature and requires the input 
of specialists of bibliometric research databases. Despite 
this, the number of published articles available for each 
of the PICOT questions was surprisingly low given the 
long period that was scrutinized (10  years), especially 
for PICOT questions 2 (influence of device type on the 
effectiveness of maintenance ICS therapy, n = 7 papers) 
and 3 (influence of current active smoking on the effec-
tiveness of ICS-containing maintenance therapy regi-
men, n = 3 papers). This illustrates that observational 
effectiveness research in asthma is still infrequently per-
formed or reported despite the clear need for real-life 
data to complement classical RCTs by answering differ-
ent study questions including to, better assess the extent 
to which their results can be generalised, and identify the 
best target populations. Inhalation technique is known to 
be poor overall with at least 50% of the patients making 
manipulation and/or inhalation errors, which is associ-
ated with poor control of asthma and chronic obstructive 
pulmonary disease (COPD) [6, 7, 78–80]. This has led 
to the development of new devices aiming at facilitating 
the use of inhaled therapy [81]. However, none of these 
devices can be considered as ideal [82], making it neces-
sary to determine whether some are more effective than 
others in real-life populations, as opposed to RCTs popu-
lations in which patients are specifically educated to use 
studied devices properly. Regarding smoking asthmatics, 
in vitro studies showed that smoking decreases the sen-
sitivity of inflammatory cells to corticosteroids, at least 
in part through oxidative stress-induced decreases in the 
cofactor histone deacetylase 2 [83, 84]. RCTs also showed 
a decreased clinical effect of ICS in smoking asthmatics 
[4]. How this translates within real-life populations is 
largely unknown. Altogether, real-life effectiveness stud-
ies might be useful to better identify subpopulations with 
specific responses to therapy, allowing more effective 
treatment individualisation.
The number of articles published in the 10-year period 
of interest regarding the influence of adherence and par-
ticle size on the effectiveness of maintenance ICS therapy 
was higher than for the two previous topics mentioned 
above. However, it remained insufficient given the impor-
tance of these issues. More specifically, although poor 
adherence has been associated with both poor inhaler 
technique and poor disease outcomes [78, 85], the level 
of adherence required to achieve better control is dif-
ficult to determine from RCTs. RCT-reported adher-
ence is believed to be markedly higher than in routine 
care, although even relatively small differences can be 
associated with marked differences in outcomes [86]. 
The search strategy retrieved 24 articles on this topic. 
While it has been shown with beclomethasone dipropi-
onate that smaller particle size allows a decrease in the 
nominal dose required to achieve a given physiologi-
cal effect [87], whether this translates into an improved 
benefit-risk ratio is unknown, and could be influenced by 
inhaler technique: the efficacy of extra-fine particle aero-
sols seems to be less dependent on inhalation technique 
[88, 89]. Only real-life studies where patients use inhal-
ers with their “natural” technique could help answering 
this question. Twelve such studies were found to inform 
PICOT question 4.
Quality assessment
A common limitation of analysed papers was the lack 
of precise clinical data available to ensure that patients 
of compared groups were 100% comparable at baseline. 
To minimize the impact of confounding (bias), most 
studies used statistical strategies including matching 
(exact or propensity score-based) and adjustments for 
variables differing between groups during the baseline 
period. These strategies could not, however, account for 
variables that were entirely absent from the databases. 
For instance, in most studies lung function data (e.g., 
FEV1) or questionnaire-measured level of asthma con-
trol were not available; so proxies for control were used 
although they were not necessarily strictly concordant 
with questionnaire results, e.g., due to time frame differ-
ences. In addition, some studies did not report sufficient 
detail on baseline population characteristics, making it 
difficult to assess their quality with a high level of con-
fidence. These points reflect the lack of 100% concord-
ance between raters, as outlined above. To deal with this 
difficulty, a third rater intervened in all cases of discord-
ance between the two initial raters. Ultimately, 48% (see 
Fig.  4) of eligible papers were considered of sufficient 
quality to be analysed further in terms of their results and 
how these could inform current knowledge and guideline 
recommendations.
There was a marked “research team” bias since 16 arti-
cles (34.8%) came from a single research team (references 
[32, 34, 40, 58, 60–65, 67–71, 76] for the 4 PICOT ques-
tions, respectively), among which only 3 (18.8%) [58, 64, 
76] were rejected based on quality assessment (vs. 52% 
of all articles). To avoid possible reviewing bias raters 
of a given paper could not belong to or collaborate with 
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the research team(s) of the authors. Thus, this observa-
tion suggests the importance of experience in the field of 
observational research to increase the likelihood of high-
quality methods.
Literature analysis
As already outlined, evidence from real-life effectiveness 
research can complement RCTs in several ways [1, 9]. 
First, by determining whether results of RCTs are appli-
cable to broader populations receiving usual care, or to 
populations excluded from RCTs. Second, by exploring 
whether some subgroups may respond better than oth-
ers, or could be at increased risk of side-effects. Third, by 
raising hypotheses on treatments effects or differences 
unsuspected in RCTs. The PICOT questions selected by 
the Task Force addressed several of these general issues: 
PICOT questions 1 and 3 (adherence and smoking) dealt 
with specific populations usually excluded from RCTs, 
i.e., poorly adherent patients and smokers, while the two 
other PICOT questions (2 and 4) dealt with possible dif-
ferences between treatments that could not be convinc-
ingly demonstrated in RCTs. Corresponding hypotheses 
are that some devices may be associated with better out-
comes due to improved ease-of-use or patient’s pref-
erence, leading to better adherence (PICOT question 
2), and that extra-fine particles might be more effective 
to administer asthma maintenance treatments due to 
improved lung deposition and distribution to the distal 
airways (PICOT question 4).
Influence of adherence to ICS therapy on asthma outcomes 
(PICOT question 1)
Overall the observational research literature analysed 
here shows that poor adherence is associated with poor 
outcomes [38, 42–49]. However, the studies did not 
define thresholds of adherence which are reliably asso-
ciated with improved outcomes. Thus, further analyses 
specifically designed to address this issue are needed. 
Results from observational studies suggesting that LTRA 
may be more effective than ICS in obtaining control 
in non-adherent patients (while the opposite is true for 
adherent patients [38]) are in line with those of a prag-
matic randomized trial, which found similar effective-
ness of these two drug classes in a real-life setting [90]. 
These data contrast with that of classical RCTs, which 
found greater efficacy of ICS [91]. This discrepancy might 
relate to differences in adherence, which is expected to be 
greater in classical RCTs’ patients than in real-life popu-
lations, in which it could be superior with an oral drug 
than with an inhaled treatment. The reluctance of some 
patients to take corticosteroids might also play a role.
Influence of smoking on asthma outcomes in patients 
receiving ICS therapy (PICOT question 3)
One study found that asthma control was impaired by 
smoking [33], which confirms previous evidence [92]. 
However, this study did not report differential treat-
ment effects in patients with different smoking-related 
behaviours, contrary to results of previous RCTs [4] 
and in vitro studies on smoking-induced mechanisms of 
decreased sensitivity to corticosteroids [83, 84]; this dis-
crepancy might be the consequence of intricate factors 
influencing the effects of maintenance therapy including 
adherence to treatments. In addition, the findings from 
this study need to be interpreted with caution due to sev-
eral limitations (high drop-out rate, no adjustment nor 
matching, few clinical data available) that prevent eleva-
tion of the evidence quality level provided by this article. 
The results of another study suggest a beneficial effect 
of extra-fine versus fine particle ICS in smokers and ex-
smokers [65]. However, although patients were matched 
and analyses were adjusted, differential treatment effect 
was only an exploratory objective of the study. Overall, 
this topic clearly requires additional research to disentan-
gle the influence of smoking versus other factors modu-
lating asthma control and treatment effects.
Influence of device type for ICS therapy on asthma outcomes 
(PICOT question 2)
Regarding PICOT question 2, the main findings from 
observational studies were that mixing devices in a sin-
gle patient or switching devices without proper support 
are associated with impaired asthma control [60, 62]. 
This finding is especially important in the context of con-
strained economic resources, leading some healthcare 
systems to recommend treatment substitutions by less 
costly generic (same device) or hybrid (different device) 
alternatives, whenever available. Regarding direct devices 
comparisons, findings are contradictory; one study con-
cluded that an MDI is associated with better outcomes 
than a DPI (in patients receiving an ICS/LABA combi-
nation [61]), while the other study by the same research 
team suggested that a breath-actuated inhaler or a DPI 
were more effective than a MDI (to deliver ICS) [34]. The 
first of these findings was rather unexpected as DPIs were 
developed to alleviate the need for patients to coordinate 
the timing of actuation and breath intake [6, 81], which 
is a common inhaler technique error among MDIs users 
[78]. It could be the result of wider patient preference for 
MDIs leading to increased adherence and subsequently 
better outcomes than for DPIs. This hypothesis could 
not, however, be tested in the study. The second finding 
could relate to improved ease-of-use and/or adherence 
of BAIs and DPIs (compared to MDIs); this needs to be 
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further assessed in future studies that minimise potential 
confounding factors. The apparent discrepancy between 
these studies could also relate to differences between the 
open inclusion of all DPI devices in the first study, all 
of which have unique characteristics, compared to the 
restriction to a single, specific DPI in the second study 
[34, 61]. Again, despite the constantly growing number 
of available inhaler devices, each of which offers potential 
advantages or drawbacks as compared to their predeces-
sors and alternatives, only a few studies have been spe-
cifically designed to compare clinical outcomes between 
different devices. This is only partial due to the limited 
number of pharmacological agents administered using 
different devices.
Influence of ICS particle size on asthma outcomes (PICOT 
question 3)
Several studies (most performed by a single research 
group) found that asthma outcomes were better in real-
life patients receiving ICS or ICS-LABA combinations 
delivered by extra-fine rather than fine particle formula-
tions [32, 40, 67–72]. These studies followed strict pro-
cesses to minimize severity biases, including matching 
and adjustment strategies. However, as always in obser-
vational database research, it is not possible to totally 
exclude residual confounders that would be detected only 
if full clinical data were available. Importantly, the selec-
tion and quality assessment processes used here were 
subsequently applied to a recently published systematic 
review and metaanalysis on this topic [93].
Strengths and limitations
This is the first initiative to develop and use a quality-
assessment tool specifically designed to aid appraisal of 
observational asthma research. Although RELEVANT 
could be used in other fields, testing was performed using 
articles reporting results from effectiveness studies in 
asthma. The Task Force systematically reviewed previ-
ous quality assessment tools for observational research, 
selected items and revised the incorporated quality 
domains and items based on pilot and extended pilot 
testing. This provided an opportunity to improve item 
selection and formulation and to reduce and refine the 
items classification into primary and secondary items to 
aid inter-rater agreement.
The final literature analysis served as a validation pro-
cess confirming the applicability of the tool and its rel-
evance for quality assessment with the aim of informing 
guidelines and clinicians. Some limitations need to be 
acknowledged. First, the process could be applied only 
to a limited number of PICOT questions consider-
ing the high burden of each set of analyses. To limit the 
impact of a biased selection of questions, a consensus 
on prioritisation was reached not only within the Task 
Force but also through a poll among REG and EAACI 
members. Similarly, a large number of REG and EAACI 
members contributed to the literature analysis, to limit 
reviewing biases. Systematic literature appraisal is time- 
and resource-consuming. Ultimately the use of stand-
ardised tools such as RELEVANT should facilitate this 
activity but the process still requires the involvement of 
experienced reviewers. The limited number of high-qual-
ity real-life comparative effectiveness research studies 
retrieved here underlines the need for a more extensive 
“real-life research culture”.
Opportunities for future research and initiatives
Comprehensive quality assessment tools are now avail-
able, not only for efficacy trials (e.g., CONSORT State-
ment) [94], but also for their pragmatic counterparts 
(CONSORT Statement extension) [95], for observa-
tional studies in epidemiology (e.g., STROBE statement) 
[96] and, more specifically, for pharmacoepidemiology 
and pharmacovigilance studies (EMA-ENCePP check-
list for study protocols) [22]. Another useful initiative 
called SPIRIT has recently published recommendations 
for describing clinical trials protocols [23]. Quality crite-
ria and minimal datasets requirements for observational 
studies are also the topic of the UNLOCK initiative [24]. 
For meta-analyses, the QUOROM (quality of reporting 
of meta-analysis) reporting guideline and the PRISMA 
(preferred reporting items for systematic reviews and 
meta-analyses) guidance seeks to improve the reporting 
of key information [19, 97]. RELEVANT now provides a 
quality assessment tool specifically developed for real-life 
effectiveness research, which can be applied to determine 
whether and how study results can be used to inform 
guidelines or clinical decision-making. It may also help 
guide the development of observational research pro-
tocols and study dissemination. We obviously welcome 
input on the RELEVANT tool from the broader commu-
nity to improve its usefulness.
Conclusions
The EAACI-REG Task Force developed and tested RELE-
VANT, a quality assessment tool for real-life comparative 
effectiveness observational research. The tool was specifi-
cally used to evaluate literature relating to PICOT ques-
tions pertinent to current evidence gaps around existing 
asthma interventions, but can also be used in other areas 
of medicine. It is hoped that the availability of this tool 
will assist the expansion of high-quality real-life effec-
tiveness research in the field of respiratory medicine and 
allergology. Importantly, several results of the literature 
analysis conducted using the RELEVANT tool could lead 
to changes in clinical practice.
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